Thanks Bernsta. Link works well and report can be downloaded as...

Thanks Bernsta. Link works well and report can be downloaded as a PDF - for posterity.

I think it's becoming increasingly clear that the market is only just starting to grasp the potential here. Previously I think it has been too fixated on existing markets (e.g. Qbrexza making only $25m/yr). Now it's starting to understand that the monumental blitzkrieg launching strategy that BOT have planned and the mechanisms with which they will bring Sofdra to the attention of millions and millions of sufferers, as well as the demonstrated overwhelming success in Japan already (350,000 units sold in the last 12 months!), has freakish potential!

Following FDA Approval, If BOT get only 1% of people already seeking help from a dermatologist, plus 1% of the 6.3m quietly suffering at home, Euroz are valuing BOT at 95c. Imagine 2% or 3%!

Brand new drug in the treatment of PAH (first ever in I don't know how long), the best performing topical available on the market, marketed directly to 50,000 members of the Hyperhidrosis society + marketed via the internet to millions and millions of punters at home + salespeople in dermatology offices, and at a cost to the insured end-user (85% of US citizens) of between $0-$50/mnth. What's not to love!